Novotech, a top global clinical trial provider, partners with biotech and pharma to speed siRNA therapeutic development.

Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...

Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...

The company's first siRNA drug could be in the clinic by the end ... will help the company land its first small-interfering RNA therapeutic in a clinical trial by late 2026 or early 2027.

Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA) for RN0361-an APOC3 ...

The study demonstrates that this RNAi approach shuts down vital fungal genes, thereby inhibiting pathogen growth - a ...

Home > Pressemitteilung: Major Progress in the Development of ...

Würzburg researchers present a new strategy against the life-threatening fungus Aspergillus fumigatus. They combine RNA ...

by the U.S. Food and Drug Administration (FDA) for RN0361-an APOC3 targeted siRNA (small interfering RNA) therapeutic for severe hypertriglyceridemia (SHTG), mixed dyslipidemia, and familial ...

Healthee, a leader in AI-driven health benefits navigation, is expanding its employer-focused value proposition through a new partnership with Northwind Pharmaceuticals, a transparent pass-through ...